The global mycoplasma testing market is expected to reach a value of USD 1.4 billion by 2025, according to a new report by Grand View Research, Inc. With growing R&D investments in the field of life sciences, the demand for mycoplasma testing products are anticipated to rise in the near future. Huge opportunities in the life sciences segment are spurring the market growth. Hence, a large amount of investment is being made in the biotechnology and pharmaceutical industries with rising level of healthcare spending across the globe. This is expected to trigger high growth of mycoplasma testing market.
Investment in R&D activities by pharmaceutical and biotechnology companies is increasingly being supported by the government. Researches involving drug discovery and development, receive funding from the governmental bodies to a great extent. Moreover, governmental initiatives in the form of awareness campaigns for chronic diseases such as cancer are also encouraging research-based activities. Thus, the aforementioned factors are expected to drive the market growth.
Mycoplasma contamination of cell culture is a growing concern for most of the research scientists for decades. Mycoplasma infection arises majorly from laboratory workers as human mycoplasma contamination occurs at a faster rate. In order to combat further contamination, mycoplasma tests are being conducted, which is expected to increase the demand of the related products.
To request a sample copy or view summary of this report, click the link below:
Further Key Findings From the Study Suggest:
In 2016, kits & reagents dominated the market and is also expected to show highest CAGR over the forecast period owing to its wider application in mycoplasma tests
Amongst the technology segment, Polymerase Chain Reaction (PCR) held the largest share in 2016 owing to the delivery of fast & accurate results associated with this technology
Cell line testing is anticipated to exhibit highest CAGR over the forecast period due to the increasing risk of cell line contamination
In 2016, pharmaceutical and biotechnology companies accounted for the largest market share due to rising number of research activities in drug discovery and development
North America dominated the market in 2016 owing to rising healthcare spending levels and government funding for life science-related research
Some of the key players are Merck KGaA; Sigma-Aldrich Co.; Thermo Fisher Scientific; Lonza Group Ltd.; Charles River Laboratories International, Inc.; PromoCell GmbH; and Bionique Testing Laboratories, Inc.
Grand View Research has segmented the mycoplasma testing market on the basis of product, technology, application, end-use, and region:
Mycoplasma Testing Product Outlook (Revenue, USD Million, 2014 - 2025)
Kits & Reagents
Nucleic Acid Detection Kits
Standards & Controls
Mycoplasma Testing Technology Outlook (Revenue, USD Million, 2014 - 2025)
Microbial Culture Techniques
Mycoplasma Testing Application Outlook (Revenue, USD Million, 2014 - 2025)
Cell Line Testing
End of Production Cells Testing
Mycoplasma Testing End-Use Outlook (Revenue, USD Million, 2014 - 2025)
Academic Research Institutes
Contract Research Organizations
Pharmaceutical & Biotechnology Companies
Mycoplasma Testing Regional Outlook (Revenue, USD Million, 2014 - 2025)
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.